Summary
Retinoblastoma protein (Rb) expression has been correlated with state of differentiation, proliferation rate, and metastatic potential in breast adenocarcinomas and established cell lines. These observations, based on immunoreactivity of total Rb rather than hypophosphorylated protein, do not address the relationship between functional Rb and indicators of an aggressive transformed cellular phenotype. We hypothesized that the distribution of functional Rb and the kinetics of Rb phosphorylation would differ between cell lines representing immortalized mammary epithelium (MCF10A), differentiated nommetastatic mammary adenocarcinoma (MCF-7), and poorly differentiated, highly metastatic mammary adenocarcinoma (MDA-MB-231) and that these differences would be informative of the cellular phenotype. Direct immunofluorescence microscopy was used to compare qualitatively the subcellular localization of total and hypophosphorylated Rb protein in synchronized and asynchronous cells. This technique was also used to quantitatively assess the amounts of hypophosphorylated Rb throughout the cell cycle in these representative cell lines. Total Rb stained more prominently than hypophosphorylated Rb in the nucleus of all asynchronous cells. Rb phosphorylation was more rapid in MCF-7 cells than in MCF10A cells, whereas Rb dephosphorylation appeared deregulated in MDA-MB-231 cells. We conclude that assessment of hypophosphorylated Rb may be more useful than assessment of total Rb for the evaluation of transformed breast adenocarcinoma phenotypes.
Similar content being viewed by others
References
Andreassen, A.; Lacriox, F. B.; Villa-Moruzzi, E., et al. Differential subcellular localization of protein phosphatase-1 α, γ1, and δ isoforms during both interphase and mitosis in mammalian cells. J. Cell Biol. 141:1207–1215; 1998.
Bartek, J.; Vojtesek, B.; Grand, R.J., et al. Cellular localization and T antigen binding of the retinoblastoma protein. Oncogene 7:101–108; 1992.
Berndt, N.; Dohadwala, M.; Liu, C. W. Constitutively active protein phosphatase-1 alpha causes Rb-dependent G1 arrest in human cancer cells. Curr. Biol. 7:375–386; 1997.
Bookstein, R.; Shew, J. Y.; Chen, P. L., et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712–715; 1990.
Borg, A.; Zhang, Q. X.; Alm, P., et al. The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. Cancer Res. 52:2991–2994; 1992.
Botos, J.; Smith, R., III; Kochevar, D. T. Rb function is a better indicator of cellular phenotype in cultured breast adenocarcinoma cells than Rb expression. Exp. Biol. Med. 227: 2002.
Brunk, C.; Jones, K. C.; James, T. W. Assay for nanogram quantities of DNA in cellular homogenates. Anal. Biochem. 92:497–500; 1979.
Buchkovich, K.; Duffy, L. A.; Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097–1105; 1989.
Cailleau, R.; Young, R.; Olive, M., et al. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:661–674; 1974.
Caputi, M.; Esposito, V.; Groger, A. M., et al. RB growth control evasion in lung cancer. Anticancer Res. 18:2371–2374; 1998.
Coleman, A. W.; Goff, L. J. Applications of fluorochromes to pollen biology, mithamycin and 4′6-diamidino-2-phenylindole (DAPI) as vital stains and for quantitation of nuclear DNA. Stain Technol. 60:145–154; 1985.
Cowell, J. K.; Bia, B.; Akoulitchev, A. A novel mutation in the promoter region in a family with a mild form of retinoblastoma indicates the location of a new regulatory domain for the RB1 gene. Oncogene 12:431–436; 1996.
Dublin, E. A.; Patel, N. K.; Gillet, C. E., et al. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int. J. Cancer 79:71–75; 1998.
Ellenberg, J.; Siggia, E. D.; Moreira, J. E., et al. Nuclear membrane dynamics and reassembly in living cells: targeting of an inner nuclear membrane protein in interphase and mitosis. J. Cell Biol. 138:1193–1206; 1997.
Ezhevsky, S. A.; Nagahara, H.; Vocero-Arbani, A. M., et al. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc. Natl. Acad. Sci. USA 97:10699–10704; 1997.
Fujita, T.; Ohtani-Fujita, N.; Sakai, T. Identification of an RB-responsibe region in the 5′ untranslated region of the RB gene. Cancer Lett. 101:149–157; 1996.
Fung, Y. K.; T'Ang, A. The role of the retinoblastoma gene in breast cancer development. in: Dickinson, R. B.; Lippman, M. E., ed. Genes, oncogenes, and hormones: advances in cellular and molecular biology of breast cancer. Boston, MA: Kluwer Academic Publishers; 1991:59–68.
Gope, R.; Gope, M. L. Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer. Mol. Cell. Biochem. 110:123–133; 1992.
Gottardis, M. M.; Saceda, M.; Garcia-Morales, P., et al. Regulation of retinoblastoma gene expression in hormone-dependent breast cancer. Endocrinology 136:5659–5665; 1995.
Gouyer, V.; Gazzeri, S.; Brambilla, E., et al. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuroendocrine lung carcinomas. Int. J. Cancer 58:818–824; 1994.
Gray-Bablin, J.; Zalvide, J.; Fox, M. P., et al. Cyclin E, a redundant cyclin in breast cancer. Proc. Natl. Acad. Sci. USA 93:15215–15220; 1996.
Harbour, J. W.; Lai, S.-L.; Whang-Peng, J., et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353–357; 1988.
Helin, K. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 8:28–35; 1998.
Herwig, S.; Strauss, M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur. J. Biochem. 246:581–601; 1997.
Horowitz, J. M.; Park, S. H.; Bogenmann, E., et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl. Acad. Sci. USA 87:2775–2779; 1990.
Horwitz, K. B.; Zava, D. T.; Thilagar, A. K., et al. Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res. 38:2434–2437; 1978.
Jaumot, M.; Estanyol, J. M.; Serratosa, J., et al. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements. Hepatology 29:385–395; 1999.
Jiang, H.; Chou, H. S.; Zhu, L. Requirement of cyclin E-cdk2 inhibition in p16INK4a-mediated growth suppression. Mol. Cell. Biol. 18:5284–5290; 1998.
Juan, C.; Gruenwald, S.; Darzynkiewicz, Z. Phosporylation of retinoblastoma susceptibility gene protein assayed in individual lymphocytes during their mitogenic stimulation. Exp. Cell Res. 237:104–110; 1998.
Kanoe, H.; Nakayama, T.; Murakami, H., et al. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. Anticancer Res. 18:2317–2322; 1998.
Kapuscinski, J.; Szer, W. Interactions of 4′6-diamidino-2-phenylindole with synthetic polynucleotides. Nucleic Acids Res. 6:3519–3534; 1979.
Keyomarsi, I.; Pardee, A. B. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. USA 90:1112–1116; 1993.
Kwon, T. K.; Buchholz, M. A.; Gabrielson, E. W., et al. A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells. Oncogene 11:2077–2083; 1995.
Lee, W. H.; Bookstein, R.; Hong, F. et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:1394–1399; 1987.
Lee, E. Y.; To, H.; Shew, J. Y., et al. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science (Wash. DC) 241:218–221; 1988.
Lundberg, A. S.; Weinberg, R. A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18:753–761; 1998.
Mack, P. C.; Chi, S. G.; Meyers, F. J., et al. Increased RBI abnormalities in human primary prostate cancer following combined androgen blockade. Prostate 34:145–151; 1998.
Mancini, M. A.; Shan, B.; Nickerson, J. A., et al. The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated protein. Proc. Natl. Acad. Sci. USA 91:418–422; 1994.
Marsh, K. L.; Varley, J. M. Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br. J. Cancer 77:1460–1468; 1998.
Mittnacht, S. Control of pRB phosphorylation. Curr. Opin. Genet. Dev. 8:21–27; 1998.
Mittnacht, S.; Hinds, P. W.; Dowdy, S. F., et al. Modulation of retinoblastoma protein activity during the cell cycle. Cold Spring Harb. Symp. Quant. Biol. 56:197–209; 1991a.
Mittnacht, S.; Weinberg, R. A. G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 65:381–393; 1991b.
Moore, J.D.; Yang, J.; Truant, R., et al. Nuclear import of cdk/cyclin complexes: identification of distinct mechanisms for import of cdk2/cyclin E and cdc2/cyclin B1. J. Cell Biol. 144:213–224; 1999.
Musgrove, E. A.; Lilischkis, R.; Cornish, A. L., et al. Expression of the cyclin-dependent kinase breast cancer. Int. J. Cancer 63:584–591; 1995.
Nelson, D. A.; Krucher, N. A.; Ludlow, J. W.. High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J. Biol. Chem. 272:4528–4535; 1997a.
Nelson, D. A.; Ludlow, J. W. Characterization of the mitotic phase pPb-directed protein phosphatase activity. Oncogene 14:2407–2415; 1997b.
Ohtani-Fujita N.; Fujita, T.; Aoike, A., et al. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8:1063–1067; 1993.
Ozaki, T.; Saijo, M.; Murakami, K., et al. Complex formation between lamin A and the retinoblastoma gene product: identification of the domain on lamin A required for its interaction. Oncogene 9:2649–2653; 1994.
Pietilainen, T.; Lipponen, P.; Altomaa, S., et al. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur. J. Cancer 31A:329–333; 1995.
Pines J. Cyclins and cyclin-dependent kinases—a biochemical view. Biochem. J. 308:697–711; 1995.
Planas-Silva, M. D.; Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17:4059–4069; 1997.
Porter-Jordan, K.; Lippman, M. E. Overview of the biologic markers of breast cancer. Hematol. Oncol. Clin. N. Am. 8:73–100; 1994.
Puntoni, F.; Villa-Moruzzi, E. Association of protein phosphatase-1 delta with the retinoblastoma protein and reversible phosphatase activation in mitotic HeLa cells and in cells released from mitosis. Biochem. Biophys. Res. Commun. 235:704–708; 1997a.
Puntoni, E.; Villa-Moruzzi, E. Phosphorylation of protein phosphatase-1 isoforms by cdc2 cyclin B in vitro. Mol. Cell. Biochem. 171:115–120; 1997b.
Puntoni, F.; Villa-Moruzzi, E. Protein phosphatase-1 alpha, gamma-1, and delta—changes in phosphorylation and activity in mitotic HeLa cells released from mitotic block. Arch. Biochem. Biophys. 340:177–184; 1997c.
Russo, A. A.; Tong, T.; Lee, J.-O., et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk 6 by the tumor suppressor p16INK4a. Nature 17:237–243; 1998.
Scovassi, A. I.; Stivala, L. A.; Rossi, L., et al. Nuclear association of cyclin D1 in human fibroblasts: tight binding to nuclear structures and modulation by protein kinase inhibitors. Exp. Cell Res. 237:127–134; 1997.
Shekhar, P. V. M.; Chen, M. L.; Werdell, J., et al. Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells—a model for early breast cancer. Int. J. Oncol. 13:907–915; 1998.
Soule, H. D.; Maloney, T. M.; Wolman, S. R., et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50:6075–6086; 1990.
Soule, H. D.; Vazquez, J.; Long, A., et al. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51:1409–1416; 1973.
Stirzaker, C.; Millar, D. S.; Paul, C. L., et al. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res. 57:2229–2237; 1997.
Taylor, C. R.; Cote, R. J. Immunohistochemical markers of prognostic value in surgical pathology. Histol. Histopathol. 12:1039–1055; 1997.
T'Ang, A.; Varley, J. M.; Chakraborty, R., et al. Structural rearrangements of the retinoblastoma gene in human breast carcinoma. Science 242:263–266; 1988.
Varley, J. M.; Armour, J.; Swallow, J. E., et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumors. Oncogene 4:725–729; 1989.
Xu, L.; Sgroi, D.; Stemer, C. J., et al. Mutational analysis of CDKN2 (MTS1/p16 ink4) in human breast cancer. Cancer Res. 54:5262–5264; 1994.
Yen, A.; Coder, D.; Varvayanis, S. Concentration of RB protein in nucleaus vs. cytoplasm is stable as phosphorylation of RB changes during the cell cycle and differentiation. Eur. J. Cell Biol. 72:159–165; 1997.
Zhou, J.-N.; Linder, S. Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines. Anticancer Res. 16:1931–1936; 1996.
Zwijsen, R. M. L.; Klompmaker, R.; Wientjens, E. B. H. G. M., et al. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol. Cell. Biol. 16:2554–2560; 1996.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Botos, J., Barhoumi, R., Burghardt, R. et al. Rb localization and phosphorylation kinetics correlate with the cellular phenotype of cultured breast adenocarcinoma cells. In Vitro Cell.Dev.Biol.-Animal 38, 235–241 (2002). https://doi.org/10.1290/1071-2690(2002)038<0235:RLAPKC>2.0.CO;2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1290/1071-2690(2002)038<0235:RLAPKC>2.0.CO;2